Molecular Therapy-Oncolytics

Papers
(The H4-Index of Molecular Therapy-Oncolytics is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Promoting role of pentraxin-3 in esophageal squamous cell carcinoma164
Targeting carcinoembryonic antigen-expressing tumors using a novel transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1122
esRAGE-expressing oHSV enhances anti-tumor efficacy by inhibition of endothelial cell activation113
Efficacy of a third-generation oncolytic herpes simplex virus in refractory soft tissue sarcoma xenograft models83
Sperm protein 17 targeting for epithelial ovarian cancer treatment in the era of modern immunoengineering67
Ferroptosis gene signature in cholangiocarcinoma64
The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy60
Deletion of immunomodulatory genes as a novel approach to oncolytic vaccinia virus development53
Lazertinib improves the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 overexpression cancer cells in vitro, in vivo, and ex vivo53
Spatiotemporal analysis of induced neural stem cell therapy to overcome advanced glioblastoma recurrence53
Metabolic remodeling in tumor-associated macrophages contributing to antitumor activity of cryptotanshinone by regulating TRAF6-ASK1 axis51
Anti-CAIX BBζ CAR4/8 T cells exhibit superior efficacy in a ccRCC mouse model50
A New Tool for CRISPR-Cas13a-Based Cancer Gene Therapy49
Reinvigoration of innate and adaptive immunity via therapeutic cellular vaccine for patients with AML47
Transcriptional landscape associated with TNBC resistance to neoadjuvant chemotherapy revealed by single-cell RNA-seq45
A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers44
Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma43
Synthetic mRNA-based gene therapy for glioblastoma: TRAIL-mRNA synergistically enhances PTEN-mRNA-based therapy43
Cancer stem/progenitor signatures refine the classification of clear cell renal cell carcinoma with stratified prognosis and decreased immunotherapy efficacy42
lncRNA RP11-147L13.8 suppresses metastasis and chemo-resistance by modulating the phosphorylation of c-Jun protein in GBC42
The miR-23a/27a/24-2 cluster promotes postoperative progression of early-stage non-small cell lung cancer40
PROTACs in gastrointestinal cancers39
miR-519d-3p suppresses tumorigenicity and metastasis by inhibiting Bcl-w and HIF-1α in NSCLC39
Circular RNA circLAMA3 inhibits the proliferation of bladder cancer by directly binding an mRNA38
Oncolytic herpes simplex virus armed with a bacterial GBP1 degrader improves antitumor activity38
Knockdown of LRRN1 inhibits malignant phenotypes through the regulation of HIF-1α/Notch pathway in pancreatic ductal adenocarcinoma37
CAFs/tumor cells co-targeting DNA vaccine in combination with low-dose gemcitabine for the treatment of Panc02 murine pancreatic cancer36
miR-1207-5p suppresses laryngeal squamous cell carcinoma progression by downregulating SKA3 and inhibiting epithelial-mesenchymal transition35
Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success?34
Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapy34
Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity34
Potential for reversing miR-634-mediated cytoprotective processes to improve efficacy of chemotherapy against oral squamous cell carcinoma33
In vivo DNA-launched bispecific T cell engager targeting IL-13Rα2 controls tumor growth in an animal model of glioblastoma multiforme33
0.057585954666138